Biocryst Pharmaceuticals Inc (BCRX)

$4.5

-0.08

(-1.75%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Biocryst Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 68.77M → 93.40M (in $), with an average increase of 9.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -36.14M → -61.73M (in $), with an average decrease of 70.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 85.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 304.4%

Performance

  • $4.50
    $4.71
    $4.50
    downward going graph

    0.0%

    Downside

    Day's Volatility :4.46%

    Upside

    4.46%

    downward going graph
  • $4.45
    $9.07
    $4.50
    downward going graph

    1.11%

    Downside

    52 Weeks Volatility :50.94%

    Upside

    50.39%

    downward going graph

Returns

PeriodBiocryst Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-20.49%
-0.7%
0.0%
6 Months
-21.84%
6.6%
0.0%
1 Year
-38.93%
3.7%
-1.5%
3 Years
-60.21%
14.0%
-21.8%

Highlights

Market Capitalization
951.4M
Book Value
- $2.21
Earnings Per Share (EPS)
-1.18
PEG Ratio
-0.28
Wall Street Target Price
13.82
Profit Margin
-68.36%
Operating Margin TTM
-40.41%
Return On Assets TTM
-11.57%
Return On Equity TTM
-1925.37%
Revenue TTM
331.4M
Revenue Per Share TTM
1.72
Quarterly Revenue Growth YOY
17.4%
Gross Profit TTM
10.9M
EBITDA
-95.9M
Diluted Eps TTM
-1.18
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.62
EPS Estimate Next Year
-0.34
EPS Estimate Current Quarter
-0.24
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Buy
    82%Buy
    17%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Biocryst Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
12
Hold
3
3
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 207.11%

Current $4.50
Target $13.82

Company Financials

FY18Y/Y Change
Revenue
20.7M
↓ 18.0%
Net Income
-101.3M
↑ 53.92%
Net Profit Margin
-490.25%
↓ 229.07%
FY19Y/Y Change
Revenue
48.8M
↑ 136.45%
Net Income
-120.1M
↑ 18.58%
Net Profit Margin
-245.86%
↑ 244.39%
FY20Y/Y Change
Revenue
17.8M
↓ 63.53%
Net Income
-196.6M
↑ 63.72%
Net Profit Margin
-1.1K%
↓ 857.71%
FY21Y/Y Change
Revenue
157.2M
↑ 782.38%
Net Income
-184.1M
↓ 6.36%
Net Profit Margin
-117.11%
↑ 986.46%
FY22Y/Y Change
Revenue
270.8M
↑ 72.31%
Net Income
-247.1M
↑ 34.26%
Net Profit Margin
-91.25%
↑ 25.86%
FY23Y/Y Change
Revenue
331.4M
↑ 22.37%
Net Income
-226.5M
↓ 8.33%
Net Profit Margin
-68.36%
↑ 22.89%
Q3 FY22Q/Q Change
Revenue
75.8M
↑ 15.71%
Net Income
-42.5M
↓ 27.76%
Net Profit Margin
-56.08%
↑ 33.74%
Q4 FY22Q/Q Change
Revenue
79.5M
↑ 4.9%
Net Income
-71.5M
↑ 68.25%
Net Profit Margin
-89.94%
↓ 33.86%
Q1 FY23Q/Q Change
Revenue
68.8M
↓ 13.54%
Net Income
-53.3M
↓ 25.45%
Net Profit Margin
-77.54%
↑ 12.4%
Q2 FY23Q/Q Change
Revenue
82.5M
↑ 19.94%
Net Income
-75.3M
↑ 41.24%
Net Profit Margin
-91.31%
↓ 13.77%
Q3 FY23Q/Q Change
Revenue
86.7M
↑ 5.15%
Net Income
-36.1M
↓ 52.01%
Net Profit Margin
-41.67%
↑ 49.64%
Q4 FY23Q/Q Change
Revenue
93.4M
↑ 7.68%
Net Income
-61.7M
↑ 70.77%
Net Profit Margin
-66.09%
↓ 24.42%
FY18Y/Y Change
Total Assets
146.8M
↓ 17.62%
Total Liabilities
97.6M
↑ 3.3%
FY19Y/Y Change
Total Assets
175.3M
↑ 19.37%
Total Liabilities
137.0M
↑ 40.39%
FY20Y/Y Change
Total Assets
334.7M
↑ 90.96%
Total Liabilities
354.0M
↑ 158.32%
FY21Y/Y Change
Total Assets
588.2M
↑ 75.72%
Total Liabilities
695.1M
↑ 96.38%
FY22Y/Y Change
Total Assets
550.0M
↓ 6.49%
Total Liabilities
844.6M
↑ 21.5%
FY23Y/Y Change
Total Assets
517.0M
↓ 6.01%
Total Liabilities
972.5M
↑ 15.14%
Q3 FY22Q/Q Change
Total Assets
558.6M
↑ 9.41%
Total Liabilities
801.3M
↑ 10.71%
Q4 FY22Q/Q Change
Total Assets
550.0M
↓ 1.54%
Total Liabilities
844.6M
↑ 5.41%
Q1 FY23Q/Q Change
Total Assets
509.7M
↓ 7.32%
Total Liabilities
838.0M
↓ 0.78%
Q2 FY23Q/Q Change
Total Assets
529.9M
↑ 3.95%
Total Liabilities
918.6M
↑ 9.61%
Q3 FY23Q/Q Change
Total Assets
-685.5M
↓ 229.37%
Total Liabilities
933.9M
↑ 1.67%
Q4 FY23Q/Q Change
Total Assets
517.0M
↓ 175.41%
Total Liabilities
972.5M
↑ 4.13%
FY18Y/Y Change
Operating Cash Flow
-92.6M
↑ 124.98%
Investing Cash Flow
4.8M
↓ 107.18%
Financing Cash Flow
62.5M
↓ 53.94%
FY19Y/Y Change
Operating Cash Flow
-89.6M
↓ 3.22%
Investing Cash Flow
77.9M
↑ 1534.52%
Financing Cash Flow
99.1M
↑ 58.55%
FY20Y/Y Change
Operating Cash Flow
-137.2M
↑ 53.17%
Investing Cash Flow
-6.9M
↓ 108.8%
Financing Cash Flow
302.7M
↑ 205.45%
FY21Y/Y Change
Operating Cash Flow
-142.2M
↑ 3.6%
Investing Cash Flow
15.8M
↓ 330.51%
Financing Cash Flow
359.7M
↑ 18.82%
FY22Y/Y Change
Operating Cash Flow
-161.9M
↑ 13.85%
Investing Cash Flow
-128.2M
↓ 911.43%
Financing Cash Flow
88.0M
↓ 75.53%
Q3 FY22Q/Q Change
Operating Cash Flow
-32.4M
↑ 16.89%
Investing Cash Flow
-69.5M
↓ 28.63%
Financing Cash Flow
76.3M
↑ 51821.77%
Q4 FY22Q/Q Change
Operating Cash Flow
-23.8M
↓ 26.49%
Investing Cash Flow
77.2M
↓ 211.03%
Financing Cash Flow
4.2M
↓ 94.5%
Q1 FY23Q/Q Change
Operating Cash Flow
-47.5M
↑ 99.22%
Investing Cash Flow
-107.1M
↓ 238.72%
Financing Cash Flow
5.1M
↑ 20.91%
Q2 FY23Q/Q Change
Operating Cash Flow
-18.8M
↓ 60.4%
Investing Cash Flow
-19.0M
↓ 82.23%
Financing Cash Flow
29.4M
↑ 478.22%

Technicals Summary

Sell

Neutral

Buy

Biocryst Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biocryst Pharmaceuticals Inc
Biocryst Pharmaceuticals Inc
-9.66%
-21.84%
-38.93%
-60.21%
-42.17%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biocryst Pharmaceuticals Inc
Biocryst Pharmaceuticals Inc
NA
NA
-0.28
-0.62
-19.25
-0.12
NA
-2.21
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biocryst Pharmaceuticals Inc
Biocryst Pharmaceuticals Inc
Buy
$951.4M
-42.17%
NA
-68.36%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • BlackRock Inc

    9.06%

  • Vanguard Group Inc

    8.62%

  • venBio Select Advisor LLC

    6.33%

  • State Street Corporation

    6.20%

  • Baker Bros Advisors LP

    4.91%

  • BRAIDWELL LP

    2.60%

Corporate Announcements

  • Biocryst Pharmaceuticals Inc Earnings

    Biocryst Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.

Organization
Biocryst Pharmaceuticals Inc
Employees
536
CEO
Mr. Jon P. Stonehouse
Industry
Health Technology

Discover More

FAQs